PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

EU OKs paediatric use of Gilead’s Epclusa

The European Commission (EC) has expanded marketing authorisation for Gilead’s Epclusa (sofosbuvir/velpatasvir/sofosbuvir) to include the treatment of children with chronic hepatitis C infection (HCV).

HCV is a life-threatening virus impacting thousands of children in Europe, which, if left untreated, can lead to severe liver complications, including liver cancer.

The decision allows use of the therapy in the EU in children as young as six years of age and weighing at least 17kg, regardless of HCV genotype or liver disease severity.

It follows Phase II clinical data showing that, in children 12 to <18 years old, treatment with Epclusa resulted in a cure rate of 93% in those with genotype 1 HCV infection and 100% in those with genotypes 2, 3, 4 and 6.

In children 6 to <12 years old, the SVR rate was 93% in those with genotype 1 HCV infection, 91% in those with genotype 3 HCV infection, and 100% in those with genotypes 2 and 4.

The safety profile of Epclusa in children six years of age and older treated was generally consistent with that observed in clinical trials in adults, in which the most common adverse reactions (incidence greater than or equal to 10%) are headache and fatigue, the firm noted.

The approval of Epclusa simplifies the selection of appropriate treatment as this pan-genotypic, pan-fibrotic regimen removes the need for some pre-treatment assessments, minimising the time from diagnosis to treatment initiation and cure, said a company spokesperson.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026